Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...
Stelo is meant for those with Type 2 diabetes as well as people who want more insight into their blood sugar levels. Here's how biosensors are growing in 2024. Jessica was a writer on the Wellness ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results